Cencora (NYSE:COR) Reaches New 1-Year Low Following Weak Earnings

Key Points

• Cencora shares hit a new 52-week low after the quarter—adjusted EPS of $4.75 missed estimates by $0.05 and revenue of $78.36B trailed the $81.09B consensus, pushing the stock as low as $244.82 from a prior close of $305.90.
• Management raised FY‑2026 EPS guidance to 17.65–17.90 citing OneOncology and specialty‑medicine strength, but set revenue guidance ($334.2B–$340.6B) below Street expectations (~$345.9B), creating a near‑term headwind.
• Analysts remain largely constructive with an average “Moderate Buy” rating and $398.17 target, while institutional investors own about 97.5% of the stock and market cap is roughly $49.8B.

Cencora, Inc. (NYSE:COR - Get Free Report)'s share price hit a new 52-week low on Wednesday after the company announced weaker than expected quarterly earnings. The company traded as low as $244.82 and last traded at $252.3750, with a volume of 820562 shares. The stock had previously closed at $305.90.

The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.80 by ($0.05). Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $78.36 billion for the quarter, compared to analysts' expectations of $81.09 billion. During the same quarter in the prior year, the firm earned $4.42 EPS. The firm's revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS.

More Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Raised FY profit/ EPS outlook: Cencora lifted its fiscal‑2026 EPS guidance to a 17.65–17.90 range (slightly above consensus), signaling confidence in full‑year profitability. Cencora raises annual profit forecast despite quarterly miss
• Positive Sentiment: OneOncology / specialty growth lift: Management pointed to steady demand for specialty medicines and OneOncology contributions as drivers of the earnings lift and improved outlook. Cencora lifts 2026 outlook after OneOncology‑fueled earnings jump
• Neutral Sentiment: Top‑line and GAAP items: Revenue rose 3.8% year‑over‑year to ~$78.4B and GAAP diluted EPS was $8.40 (reflecting notable accounting adjustments), facts that provide context but require digging into adjusted figures. Cencora Reports Fiscal 2026 Second Quarter Results
• Negative Sentiment: Quarterly miss on adjusted EPS and revenue: Adjusted EPS came in at $4.75 vs. the $4.80 consensus (a $0.05 miss) and revenue of ~$78.36B trailed analyst estimates (~$81.09B), which pressured near‑term sentiment. Cencora (COR) Misses Q2 Earnings and Revenue Estimates
• Negative Sentiment: Revenue guidance below Street: Management set fiscal‑2026 revenue guidance below consensus ($334.2B–$340.6B vs. analyst estimate ~ $345.9B), leaving a near‑term headwind despite the EPS upgrade. Cencora Reports Fiscal 2026 Second Quarter Results

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on COR. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $417.00 to $419.00 and gave the company an "overweight" rating in a report on Tuesday, February 10th. William Blair began coverage on shares of Cencora in a report on Tuesday, April 28th. They issued a "market perform" rating on the stock. Morgan Stanley set a $380.00 price objective on shares of Cencora in a report on Tuesday, March 17th. Jefferies Financial Group upgraded shares of Cencora from an "underperform" rating to a "buy" rating in a report on Thursday, January 22nd. Finally, Leerink Partners restated an "outperform" rating on shares of Cencora in a report on Tuesday, March 17th. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Cencora currently has an average rating of "Moderate Buy" and an average target price of $398.17.

Hedge Funds Weigh In On Cencora

Several institutional investors have recently bought and sold shares of COR. United Bank grew its position in Cencora by 4.5% in the 2nd quarter. United Bank now owns 7,032 shares of the company's stock valued at $2,109,000 after acquiring an additional 305 shares in the last quarter. Nebula Research & Development LLC acquired a new position in Cencora in the 2nd quarter valued at about $595,000. Treasurer of the State of North Carolina grew its position in Cencora by 7.9% in the 2nd quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company's stock valued at $25,647,000 after acquiring an additional 6,244 shares in the last quarter. Diversify Advisory Services LLC grew its position in Cencora by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company's stock valued at $747,000 after acquiring an additional 1,253 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in Cencora by 26.0% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company's stock valued at $22,025,000 after acquiring an additional 15,154 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Performance

The company has a market capitalization of $49.84 billion, a price-to-earnings ratio of 30.77, a P/E/G ratio of 1.42 and a beta of 0.64. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The firm has a 50-day simple moving average of $332.27 and a two-hundred day simple moving average of $343.21.

About Cencora

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.